In yesterday’s Wall Street session, Kintara Therapeutics Inc (NASDAQ:KTRA) shares traded at $0.38, down -3.01% from the previous session.
As of this writing, 2 analysts cover Kintara Therapeutics Inc (NASDAQ:KTRA). The consensus rating among analysts is ‘Hold’. As we calculate the median target price by taking the range between a high of $14.00 and a low of $14.00, we find $14.00. Given the previous closing price of $0.39, this indicates a potential upside of 3489.74 percent. KTRA stock price is now -88.88% away from the 50-day moving average and -90.15% away from the 200-day moving average. The market capitalization of the company currently stands at $0.67M.
There are 2 analysts who have given it a hold rating, whereas 0 have given it a buy rating. Brokers who have rated the stock have averaged $14.00 as their price target over the next twelve months.
A total of 4.37% of the company’s stock is owned by insiders.
Friday morning saw Kintara Therapeutics Inc (NASDAQ: KTRA) opened at $0.4127. During the past 12 months, Kintara Therapeutics Inc has had a low of $0.38 and a high of $15.50. As of last week, the company has a debt-to-equity ratio of 0.00, a current ratio of 1.06, and a quick ratio of 1.06. The fifty day moving average price for KTRA is $3.3620 and a two-hundred day moving average price translates $3.8572 for the stock.
The latest earnings results from Kintara Therapeutics Inc (NASDAQ: KTRA) was released for Jun, 2023. According to the Biotechnology Company, earnings per share came in at -$1.95, missing analysts’ expectations of -$1.05 by -0.9. This compares to -$3.05 EPS in the same period last year. The company reported revenue of $3.35 million for the quarter, compared to $5.46 million a year earlier. Comparatively to last year’s same quarter, the company’s quarterly revenue fell -38.64 percent.
Kintara Therapeutics Inc(KTRA) Company Profile
Kintara Therapeutics, Inc., a clinical stage drug development company, focuses on developing and commercializing anti-cancer therapies to treat cancer patients. It is developing two late-stage, Phase III-ready therapeutics, including VAL-083, a DNA-targeting agent for the treatment of drug-resistant solid tumors, such as glioblastoma multiforme, as well as other solid tumors, including ovarian cancer, non-small cell lung cancer, and diffuse intrinsic pontine glioma; and REM-001, a late stage photodynamic therapy for the treatment of cutaneous metastatic breast cancer, basal cell carcinoma nevus syndrome, and access graft failure in hemodialysis patients. Kintara Therapeutics, Inc. has a strategic collaboration with Guangxi Wuzhou Pharmaceutical (Group) Co. Ltd. to manufacture and sell VAL-083 in China. The company was formerly known as DelMar Pharmaceuticals, Inc. and changed its name to Kintara Therapeutics, Inc. in August 2020. Kintara Therapeutics, Inc. was incorporated in 2009 and is headquartered in San Diego, California.